Hepatic arterial chemotherapy for primary and metastatic liver cancers
dc.contributor.author | Ensminger, William D. | en_US |
dc.date.accessioned | 2006-09-11T18:22:38Z | |
dc.date.available | 2006-09-11T18:22:38Z | |
dc.date.issued | 1989-01 | en_US |
dc.identifier.citation | Ensminger, William; (1989). "Hepatic arterial chemotherapy for primary and metastatic liver cancers." Cancer Chemotherapy and Pharmacology 23(1): S68-S73. <http://hdl.handle.net/2027.42/46919> | en_US |
dc.identifier.issn | 0344-5704 | en_US |
dc.identifier.issn | 1432-0843 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46919 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2647314&dopt=citation | en_US |
dc.description.abstract | Hepatic arterial chemotherapy represents a means of selectively exposing hepatic tumor to cytotoxic agents. Although 5-fluoro-2′-deoxyuridine has been shown to generate a higher response rate in the treatment of colorectal liver metastases than that achieved by intravenous infusion, responses are largely incomplete and rarely of long duration. This review describes the rationale for the use of the thymidine analogs 5-bromo-2′-deoxyuridine and 5-iodo-2′-deoxyuridine in hepatic arterial infusions and indicates how combination therapy adding radiotherapy, specifically with hepatic arterially administered yttrium-90 microspheres, might generate a new, more efficient and effective therapeutic approach. | en_US |
dc.format.extent | 674166 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Cancer Research | en_US |
dc.subject.other | Oncology | en_US |
dc.title | Hepatic arterial chemotherapy for primary and metastatic liver cancers | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Upjohn Center for Clinical Pharmacology, Department of Medicine, University of Michigan Medical School, 48109, Ann Arbor, Michigan, USA; Department of Pharmacology, University of Michigan Medical School, 48109, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 2647314 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46919/1/280_2004_Article_BF00647244.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00647244 | en_US |
dc.identifier.source | Cancer Chemotherapy and Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.